Early detection of AD and AD-related dementias is critical for the development of novel therapeutic agents and for effective patient treatment and care. DCT has created a platform able to detect subtle changes in behavior indicative of early cognitive impairment by using a digital pen to record drawing motions and automatically analyzing that data using a combination of artificial intelligence and neuropsychological analysis. DCT has successfully launched its first test on the platform, DCTclockTM, which has been demonstrated to detect subtle cognitive change in early Alzheimerâs Disease (AD) and AD-related dementias earlier than standard cognitive tests, correlate with known AD biomarkers such as amyloid and tau in preclinical-AD subjects, and detect known APOE genetic risk in cognitively healthy participants. The test is FDA-cleared to market for general cognitive assessment and is currently used in multinational clinical trials, research initiatives, and by practicing clinicians for patient care. DCT is now conducting a study involving 400 participants ranging from cognitively healthy to demented to validate a tablet as input device for the drawing data, and to collect data on a set of novel tablet-based drawing tasks including: a symbol task, a visual retention task, a trail making task, a path- finding task, and a visuoconstructional task. We aim to analyze task data collected in the study to produce a set of easily-deployable, rapid, cost-effective, and sensitive tests to be used as cognitive digital biomarkers in clinical trials for AD and AD-related dementias. The first aim is to develop novel cognitive measures from these additional tests and obtain preliminary validation. Existing data will be split into training and testing sets. The training set will be analyzed to develop metrics, following an interpretable hierarchical analysis structure with low-level drawing measurements combined in a set of composite scales tied to a cognitive concept (i.e., information processing), and then further combined to obtain a simple 0-100 score for performance on the test. The testing set will be used to conduct preliminary validation consisting of a Receiver Operating Characteristic curve analysis, correlation measures to existing neuropsychological tests, and test-retest reliability measurements to ensure repeat testing stability. The second aim is to implement the developed metrics in the commercial DCT platform. Robust software will be created for the measurement, storage, and display of the novel metrics, setting a foundation to enable usage of the metrics by research and commercial partners.
Public Health Relevance Statement: Project Narrative Novel therapeutic agents for Alzheimerâs disease rely on recruiting subjects who are in the earliest stages of pre-symptomatic impairment and the ability to accurately monitor these subjects. This project will produce a set of easily-deployable, sensitive, rapid, and cost-effective tablet-based tests to be used as cognitive digital biomarkers by future clinical trials to help enable the development of new efficacious treatments for Alzheimerâs disease. The short testing time and ease of use of the technology could also enable primary care providers to detect individuals most at-risk for preclinical Alzheimerâs disease and other related dementias.
Project Terms: Algorithms; Alzheimer disease detection; Alzheimer's Disease; Alzheimer's disease related dementia; Alzheimerâs disease biomarker; Amyloid; Artificial Intelligence; base; Behavior; Behavioral; Biological Markers; care providers; Caring; Clinical Trials; cloud based; Cognition; Cognitive; cognitive change; cognitive testing; Collection; Computer software; cost effective; Data; Data Analyses; Data Collection; Data Reporting; Data Set; demented; Dementia; Development; digital; Early Diagnosis; Ensure; Environment; Foundations; Future; Genetic Risk; Goals; Health Insurance Portability and Accountability Act; Home environment; Impaired cognition; Impairment; improved; Individual; information processing; Infrastructure; input device; Intuition; Machine Learning; Measurement; Measures; memory process; Monitor; Motion; Neuropsychological Tests; Neuropsychology; novel; novel therapeutics; Paper; Participant; Patient Care; Patients; Performance; Phase; pre-clinical; processing speed; Receiver Operating Characteristics; recruit; Research; Research Personnel; Risk; Sensitivity and Specificity; signal processing; Small Business Innovation Research Grant; stability testing; Structure; System; Tablets; tau Proteins; Technology; Testing; Therapeutic Agents; Time; Training; Validation; Visit; Visual; web por
